fda bans compounded semaglutide and tirzepatide moves to remove GLP-1 medications from 503B Bulks List The Impact of New FDA
Description
Clostridium butyricum may provide antioxidant activity in the digestive system and support a healthy inflammatory response in the gut
Prospective ultrasound studies show a higher prevalence of residual gastric content in GLP-1 RA users, particularly during dose escalation or when GI symptoms are present
Complications from treated diverticulitis are rare, but some people may be at a higher risk
Here, the authors review the physiological roles of GLP-1, the potential renoprotective mechanisms of incretin-based therapies and the available renal outcome data from clinical trials.
